The content on this site is intended for healthcare professionals only
Prof Nicolas Mottet speaks to ecancer at the EMUC 2019 meeting in Vienna about the management of prostate cancer in older patients.
He gives an update on the SIOG guidelines and the new clinical trial data that supported these changes.
Prof Mottet also explores the classification of these patients as a means of valid decision-making, and the definition of "frailty" and "reversibility".
He concludes by discussing the applicability of these guidelines in under-resourced settings.
This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.
Prostate cancer
Cancer in emergencies: What can we do better to protect the most vulnerable?
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
OncoAlert Round Up for August 11th - 17th, 2023
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
Looking into the future diagnosis and treatment options for prostate cancer in Africa
Management of prostate cancer in Africa: Looking to the future
